chinese semaglutide biotech targets 2028 trial finish for spray using Wegovy's ingredient! Shanghai Shiling Pharmaceutical has announced plans to complete global clinical trials by 2028 for an innovative weight-management nasal spray that uses Novo Nordisk braces as China

Rising Number of Clinical Trials Drives Asia-Pacific The APAC clinical trials market size was estimated at US$ 18.87 billion in 2025, projected to increase to US$ 20.42 billion in 2026 and reach US$ 41.33 billion by 2035, showing a healthy CAGR of 7.16% across the forecast years

To view or add a comment, sign in Novo Nordisk has received #approval from the US Food and Drug Administration (FDA) for Wegovy HD, a once-weekly injectable #formulation of semaglutide 7.2 mg, for chronic weight management in adults with obesity

Weight loss acceleration usually becomes noticeable between weeks 4 and 8 of consistent oral semaglutide use

GLP-1 medications can cause nausea, vomiting, and gastrointestinal symptoms that may intensify nicotine withdrawal discomfort